Recent research have centered on the intersection of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GLP agonists are widely employed for addressing type 2 T2DM, their potential effects on motivation circuits, specifically mediated by dopaminergic systems, are receiving considerable intere